Displaying drugs 701 - 725 of 9450 in total
Diiodohydroxyquinoline
Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Iodoquinol is not currently available in any FDA-approved products. …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Categories: … Corticosteroids, Potent (Group III) …
Tioconazole
Tioconazole is an imidazole antifungal used to treat fungal and yeast infections. Topical formulations are used for ringworm, jock itch, athlete's foot, and tinea versicolor or "sun fungus". Tioconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In...
Approved
Matched Description: … Tioconazole is an imidazole antifungal used to treat fungal and yeast infections. ... interacts with 14-alpha demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an ... In addition to being an antifungal, tioconazole also has antibacterial effects on certain Gram-positive …
Sertindole
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of...
Approved
Investigational
Withdrawn
Matched Description: … It has once again been approved and should soon be available on the French and Australian market. …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Bexagliflozin
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is...
Approved
Investigational
Matched Description: … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with …
Cyproheptadine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Categories: … Antidepressive Agents …
Cyclobenzaprine
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Pizotifen
Pizotifen belongs to the class of antamines and is related to cyproheptadine. It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years. It exhibits weak anticholinergic, antihistamine, and antikinin actions in addition to sedative and appetite-stimulating properties . Some patients receiving pizotifen...
Approved
Matched Description: … Sandomigran is available in a number of countries but is not approved by the FDA nor EMA. ... Pizotifen hydrochloride is an active ingredient in Sandomigran, which is used for the prophylactic management …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Etonogestrel
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Approved
Investigational
Matched Description: … A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved …
Hexobendine
Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris. It has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany .
Approved
Matched Description: … It has not been approved in the United States or the United Kingdom, but has been used widely in Austria …
Prednisone
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Approved
Vet approved
Danaparoid
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International ... Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an ... In February 2022, tepotinib was approved for use in Europe.[L42200] ... Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers …
Alclofenac
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
LetibotulinumtoxinA
The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since ... [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335 ... has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved …
Emtricitabine
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of...
Approved
Investigational
Almotriptan
Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that...
Approved
Investigational
Matched Categories: … Antidepressive Agents …
CVac
Approved
Investigational
Calcium phosphate dihydrate
Approved
Varenicline
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full...
Approved
Investigational
Matched Description: … This medication is the first approved nicotinic receptor partial agonist. ... Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015 …
Ibandronate
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA...
Approved
Investigational
Nebivolol
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta...
Approved
Investigational
Finafloxacin
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
Approved
Investigational
Matched Description: … Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December …
Ferric maltol
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Description: … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability …
Idelalisib
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with …
Displaying drugs 701 - 725 of 9450 in total